Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA

This article was originally published in The Pink Sheet Daily

Executive Summary

Relatively new to the diabetes space, Boehringer Ingelheim is trying to rapidly distinguish itself in a crowded field with four products each addressing a different patient need.

You may also be interested in...



Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief

Boehringer Ingelheim submits type 2 diabetes therapy empagliflozin; Pozen seeks a partner to help it commercialize its aspirin/PPI combo following its NDA submission; Eisai gets FDA approval for pediatric use of acid reflux drug Aciphex; Merck announces FDA’s acceptance of its oral grass pollen allergy immunotherapy BLA; the EMA accepts Shionogi’s menopause drug Osphena for review, and IntelGenx submits an NDA for an oral film version of Maxalt-MLT.

Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance

Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.

Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance

Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS074307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel